{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:34:55Z","timestamp":1790872495542,"version":"4.1.0"},"reference-count":31,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>As a means of treating lymphatic metastasis from lung cancer, the pharmacokinetics and therapeutic effects of an intrapleural (ipl) implantable drug delivery system consisting of a gelatin sponge impregnated with polylactide-co-glycolide paclitaxel (PLGA-PTX) microspheres were studied. PLGA-PTX with 7% (w\/w) drug loading were incorporated into gelatin matrix. The pharmacokinetics were studied in rats with one of the following regimens: (a) Taxol 8 mg\/kg by i.v. injection; (b) Taxol 8 mg\/kg ipl; (c) PLGA-PTX (100 mg\/kg) ipl; (d) sponge containing PLGA-PTX (100 mg\/kg) ipl. PTX concentrations in lymph node and plasma were determined by liquid chromatography mass spectrometry, and the area under the curve (AUC) was calculated. Therapeutic efficacy was assessed in an orthotopic lung cancer model with tumor resection 14 days following tumor implantation. Animals were randomized to ipl placement of PLGA-PTX sponge, placebo sponge, or no treatment. Lymph node metastases were examined at 32 d. The results show that the mediastinal lymph node AUC was significantly higher with ipl. placement of PLGA-PTX sponge compared with i.v. and ipl administration of Taxol. This represents 100- to 400-fold increase of lymphatic drug exposure compared with i.v. dosing. Peak plasma concentration was significantly reduced in the PLGA-PTX sponge group compared with i.v. dosing. PLGA-PTX particles were microscopically identified in lymphatic tissue and resulted in an 80% reduction of lymphatic metastasis compared with controls. Translymphatic-targeted drug delivery significantly decreases lymphatic metastasis in an orthotopic lung cancer model. This effect may be attributable to the improved distribution of PTX to the lymphatic system. [Cancer Res 2009;69(3):1174\u201381]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-1753","type":"journal-article","created":{"date-parts":[[2009,1,28]],"date-time":"2009-01-28T04:55:08Z","timestamp":1233118508000},"page":"1174-1181","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Translymphatic Chemotherapy by Intrapleural Placement of Gelatin Sponge Containing Biodegradable Paclitaxel Colloids Controls Lymphatic Metastasis in Lung Cancer"],"prefix":"10.1158","volume":"69","author":[{"given":"Jiang","family":"Liu","sequence":"first","affiliation":[{"name":"1Institute of Medical Science, Faculty of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Meisner","sequence":"additional","affiliation":[{"name":"3Pharmaceutical Research and Development, Merck Frosst Center for Therapeutic Research, Quebec, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kwong","sequence":"additional","affiliation":[{"name":"3Pharmaceutical Research and Development, Merck Frosst Center for Therapeutic Research, Quebec, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Y.","family":"Wu","sequence":"additional","affiliation":[{"name":"2Department of Pharmaceutical Science, Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Johnston","sequence":"additional","affiliation":[{"name":"1Institute of Medical Science, Faculty of Medicine and"},{"name":"4Division of Thoracic Surgery, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"2022061701340691800_B1","unstructured":"Bunn PA, Jr., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res\u20081998; 5: 1087\u2013100."},{"key":"2022061701340691800_B2","doi-asserted-by":"crossref","unstructured":"Liptay MJ. Sentinel node mapping in lung cancer. Ann Surg Oncol\u20082004; 11: 271\u20134S.","DOI":"10.1007\/BF02523644"},{"key":"2022061701340691800_B3","unstructured":"Kuo TH, Kubota T, Watanabe M, et al. Early resection of primary orthotopically-gowing human colon tumor in nude mouse prevents liver metastasis: further evidence for patient-like hematogenous metastatic route. Anticancer Res\u20081993; 13: 293\u20137."},{"key":"2022061701340691800_B4","doi-asserted-by":"crossref","unstructured":"Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovas Surg\u20081995; 109: 120\u20139.","DOI":"10.1016\/S0022-5223(95)70427-2"},{"key":"2022061701340691800_B5","doi-asserted-by":"crossref","unstructured":"Fischer-Brugge E, Sunder-Plassmann P, Roper K. On the terminal innervation of the lymphatic vessels of the appendix, and observations on cellular processes of the blood-lymph barrier in human appendicitis. Langenbecks Arch Klin Chir Ver Dtsch Z Chir\u20081950; 265: 120\u201332.","DOI":"10.1007\/BF01405129"},{"key":"2022061701340691800_B6","unstructured":"Grotte G, Knutson RC, Bollman JL. The diffusion of dextrans of different molecular sizes to lymph and urine. J Lab Clin Med\u20081951; 38: 577\u201382."},{"key":"2022061701340691800_B7","unstructured":"Grotte G. Passage of dextran molecules across the blood-lymph barrier. Acta Chir Scand Suppl\u20081956; 211: 1\u201384."},{"key":"2022061701340691800_B8","doi-asserted-by":"crossref","unstructured":"Liu J, Wong HL, Moselhy J, Bowen B, Wu XY, Johnston MR. Targeting colloidal particulates to thoracic lymph nodes. Lung Cancer\u20082006; 51: 377\u201386.","DOI":"10.1016\/j.lungcan.2005.11.006"},{"key":"2022061701340691800_B9","doi-asserted-by":"crossref","unstructured":"Liu J, Meisner D, Kwong E, Wu XY, Johnston MR. A novel trans-lymphatic drug delivery system: Implantable gelatin sponge impregnated with PLGA-paclitaxel microspheres. Biomaterials\u20082007; 28: 3236\u201344.","DOI":"10.1016\/j.biomaterials.2007.03.022"},{"key":"2022061701340691800_B10","doi-asserted-by":"crossref","unstructured":"Perng RP, Wu MF, Lin SY, Chen YM, Lin JY, Whang-Peng J. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anticancer Drugs\u20081997; 8: 565\u201373.","DOI":"10.1097\/00001813-199707000-00003"},{"key":"2022061701340691800_B11","unstructured":"Hawley AE, Illum L, Davis SS. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res\u20081997; 14: 657\u201361."},{"key":"2022061701340691800_B12","doi-asserted-by":"crossref","unstructured":"Liggins RT, D'Amours S, Demetrick JS, Machan LS, Burt HM. Paclitaxel loaded poly(L-lactic acid) microspheres for the prevention of intraperitoneal carcinomatosis after a surgical repair and tumor cell spill. Biomaterials\u20082000; 21: 1959\u201369.","DOI":"10.1016\/S0142-9612(00)00080-6"},{"key":"2022061701340691800_B13","doi-asserted-by":"crossref","unstructured":"Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release\u20082001; 72: 191\u2013202.","DOI":"10.1016\/S0168-3659(01)00275-9"},{"key":"2022061701340691800_B14","unstructured":"Howard RB, Chu H, Zeligman BE, et al. Irradiated nude rat model for orthotopic human lung cancers. Cancer Res\u20081991; 51: 3274\u201380."},{"key":"2022061701340691800_B15","doi-asserted-by":"crossref","unstructured":"Zou YY, Fu H, Ghosh S, Farquhar D, Klostergaard J. Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin Cancer Res\u20082004; 10: 7382\u201391.","DOI":"10.1158\/1078-0432.CCR-04-0334"},{"key":"2022061701340691800_B16","unstructured":"Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol\u20081995; 22: 16\u201323."},{"key":"2022061701340691800_B17","unstructured":"Rowinsky EK. Pharmacology and metabolism. In: McGuire WG, Rowinsky EK, editors. Paclitaxel in Cancer Treatment. New York: Dekker; 1995. p. 91\u2013120."},{"key":"2022061701340691800_B18","doi-asserted-by":"crossref","unstructured":"Liebmann JE, Cook JA, Lipschultz C, et al. Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer\u20081993; 68: 1104\u20139.","DOI":"10.1038\/bjc.1993.488"},{"key":"2022061701340691800_B19","doi-asserted-by":"crossref","unstructured":"Yamori T, Sato S, Chikazawa H, Kadota T. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res\u20081997; 88: 1205\u201310.","DOI":"10.1111\/j.1349-7006.1997.tb00350.x"},{"key":"2022061701340691800_B20","doi-asserted-by":"crossref","unstructured":"Huizing MT, Keung ACF, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol\u20081993; 11: 2127\u201335.","DOI":"10.1200\/JCO.1993.11.11.2127"},{"key":"2022061701340691800_B21","doi-asserted-by":"crossref","unstructured":"Armstrong DK, Fleming GF, Markman M, Bailey HH. A Phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: A Gynecologic Oncology Group study. Gyn Oncol\u20082006; 103: 391\u20136.","DOI":"10.1016\/j.ygyno.2006.02.029"},{"key":"2022061701340691800_B22","doi-asserted-by":"crossref","unstructured":"Uhrich KE, Cannizzaro SM, Langer RS, et al. Polymeric systems for controlled drug release. Chem Rev\u20081999; 99: 3181\u201398.","DOI":"10.1021\/cr940351u"},{"key":"2022061701340691800_B23","doi-asserted-by":"crossref","unstructured":"Lu HX, Li B, Kang Y, et al. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Cancer Chemother Pharmacol\u20082007; 59: 175\u201381.","DOI":"10.1007\/s00280-006-0256-z"},{"key":"2022061701340691800_B24","unstructured":"Harper E, Dang WB, Lapidus RG, Garver RI, Jr. Enhanced efficacy of a novel controlled release paclitaxel formulation (paclimer delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res\u20081999; 5: 4242\u20138."},{"key":"2022061701340691800_B25","doi-asserted-by":"crossref","unstructured":"Pradilla G, Wang PP, Gabikian P, et al. Local intracerebral administration of paclitaxel with the Paclimer\u00ae delivery system: toxicity study in a canine model. J Neuro Oncol\u20082006; 76: 131\u20138.","DOI":"10.1007\/s11060-005-5531-z"},{"key":"2022061701340691800_B26","doi-asserted-by":"crossref","unstructured":"Demetrick JS, Liggins RT, Machan L, Davis NL, Burt HM, Hunter WL. The development of a novel intraperitoneal tumor-seeding prophylactic. Am J Surg\u20081997; 173: 403\u20136.","DOI":"10.1016\/S0002-9610(97)00079-2"},{"key":"2022061701340691800_B27","doi-asserted-by":"crossref","unstructured":"Shinohara H. Distribution of lymphatic stomata on the pleural surface of the thoracic cavity and the surface topography of the pleural mesothelium in the golden hamster. Anat Rec\u20081997; 249: 16\u201323.","DOI":"10.1002\/(SICI)1097-0185(199709)249:1<16::AID-AR3>3.0.CO;2-D"},{"key":"2022061701340691800_B28","doi-asserted-by":"crossref","unstructured":"Miura T, Shimada T, Tanaka K, Chujo M, Uchida Y. Lymphatic drainage of carbon particles injected into the pleural cavity of the monkey, as studied by video-assisted thoracoscopy and electron microscopy. J Thorac Cardiovasc Surg\u20082000; 120: 437\u201347.","DOI":"10.1067\/mtc.2000.108906"},{"key":"2022061701340691800_B29","doi-asserted-by":"crossref","unstructured":"Gupta N, Hu LJ, Deen DF. Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int J Radiat Oncol Biol Phys\u20081997; 37: 885\u201395.","DOI":"10.1016\/S0360-3016(96)00535-4"},{"key":"2022061701340691800_B30","doi-asserted-by":"crossref","unstructured":"Cahan MA, Walter KA, Colvin OM, Brem H. Cytotoxicity of Taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol\u20081994; 33: 441\u20134.","DOI":"10.1007\/BF00686276"},{"key":"2022061701340691800_B31","doi-asserted-by":"crossref","unstructured":"Wehbe T, Glantz M, Choy H, et al. Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas. J Neurooncol\u20081998; 39: 245\u201351.","DOI":"10.1023\/A:1005710710418"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/3\/1174\/2621569\/1174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/3\/1174\/2621569\/1174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:18:39Z","timestamp":1655450319000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/3\/1174\/552840\/Translymphatic-Chemotherapy-by-Intrapleural"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,29]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,1,29]]},"published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-1753","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,29]]}}}